Biotechnology News and Research

RSS

NovaDel receives Issue Notification from USPTO for oral spray

NovaDel Pharma Inc., today announced that it received an Issue Notification from the United States Patent and Trademark Office (USPTO) for a new U.S. Patent, No. 7632517, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaDel’s oral spray technology.

16 Dec 2009

Life Technologies completes previously announced acquisition of BioTrove

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has completed the previously announced acquisition of BioTrove, Inc. for an undisclosed amount.

16 Dec 2009

Idaho Technology signs licensing agreement with Kapa Biosystems

Idaho Technology, Inc. has signed a licensing agreement with Kapa Biosystems, Inc., covering reagents or methods using SYBR® Green I technology and melting curve analysis for real time PCR.

16 Dec 2009

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Pluristem Therapeutics Inc. today announced that the independent DSMB approved the advancement to the intermediate dose level of the company’s placenta derived cell therapy, PLX-PAD, in the Phase I clinical trial in Europe for the treatment of critical limb ischemia (CLI), the end stage of peripheral artery disease (PAD).

15 Dec 2009

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it has successfully released the first commercial shipments of SUMAVEL DosePro (sumatriptan injection) to Zogenix in anticipation of the planned U.S. commercial product launch scheduled in January 2010.

15 Dec 2009

Positive results from study comparing exenatide once weekly to BYETTA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced positive results from a head-to-head study comparing exenatide once weekly, an investigational diabetes therapy, to BYETTA® (exenatide) injection taken twice daily, in patients with type 2 diabetes.

15 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Can-Fite BioPharma, a biotechnology company traded on the Tel Aviv Stock Exchange, announced on December 13 the initiation of the regulatory process for a Glaucoma Phase II clinical study in Israel. Leading Medical Centers in Israel will enroll 44 patients with Ocular Hypertension or Glaucoma for the first segment of the trial, who will be treated for 16 weeks with CF101 or placebo.

15 Dec 2009

Dangers of H1N1 flu contaminated touch surfaces tour kicks-off

Dr. Bob Arnot kicks-off a national educational tour on the silent threat of H1N1 flu contaminated touch surfaces and the new biotechnology in EPA-registered SpectraSan 24 that kills bacteria, fungus and viruses including Influenza A (H1N1 or Swine Flu).

15 Dec 2009

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Chemists and biologists from the University of Bath have developed a new technique that could be used to diagnose and develop treatments for age-related conditions like Alzheimer's disease, diabetes and cancer.

15 Dec 2009

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Cardio3 BioSciences, a leading Belgian biotechnology company specialising in cell-based therapies for the treatment of cardiovascular diseases, announced today that it has completed, two months ahead of schedule, enrolment in the first stage of its pivotal Phase II/III trial of C-Cure, a unique stem cell therapy for heart failure.

15 Dec 2009

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today jointly announced that Seattle Genetics and Millennium have entered into an agreement to globally develop and commercialize brentuximab vedotin (SGN-35).

15 Dec 2009

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

ProChon Biotech, Ltd., an innovator of tissue regenerative technologies that are being developed to relieve pain and restore the mobility and quality of life for sufferers of articular cartilage injuries, today announced a significant expansion of its clinical study of the BioCart™ Cartilage Regeneration System.

15 Dec 2009

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

Elan Corporation, plc and Transition Therapeutics, Inc. today notified clinical investigators of modifications to the Phase II study AD201 and open label extension study AD251 for ELND005, a compound being developed for the potential treatment of Alzheimer’s disease.

15 Dec 2009

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

ProImmune Ltd, a leader in epitope discovery, immunogenicity and immune monitoring products and services, has launched CFSE T cell proliferation assays for immunogenicity risk assessment. The new highly sensitive assays form part of ProImmune’s REVEAL Immunogenicity System, a suite of tools used in the design and selection of biological drug leads at the preclinical stage.

15 Dec 2009

Mylan to be added to NASDAQ-100 Index

Mylan Inc. today announced that the company will be added to the NASDAQ-100 Index Dec. 21. Mylan's common shares will also be included in NASDAQ's PowerShares QQQ.

15 Dec 2009

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Dyadic International, Inc. ("Dyadic") announced today that it has extended its collaboration with The Scripps Research Institute ("Scripps") by entering into an agreement with Scripps to re-annotate the genome of Dyadic's patented and proprietary C1 fungus ("C1").

15 Dec 2009

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Teva Pharmaceutical Industries, Ltd. today announced the U.S. Food and Drug Administration (FDA) approved the newly revised prescribing information for AZILECT® (rasagiline tablets) reducing medication and food restrictions.

15 Dec 2009

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Array BioPharma Inc. and Amgen Inc.(NASDAQ: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.

14 Dec 2009

Vivakor launches new website to promote its remarkable VivaThermic Vial

Vivakor, Inc. today announced the launch of its new website promoting its remarkable VivaThermic Vial at www.vivathermic.com.

14 Dec 2009

Biotechnology News and Research

NovaDel receives Issue Notification from USPTO for oral spray

Life Technologies completes previously announced acquisition of BioTrove

Idaho Technology signs licensing agreement with Kapa Biosystems

DSMB approves advancement of PLX-PAD to intermediate dose level in Phase I clinical trial for CLI treatment

Patheon releases the first commercial shipments of SUMAVEL DosePro to Zogenix

Positive results from study comparing exenatide once weekly to BYETTA

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Can-Fite BioPharma to commence Glaucoma Phase II clinical study in Israel

Dangers of H1N1 flu contaminated touch surfaces tour kicks-off

New technique may help diagnose treatments for Alzheimer's, diabetes and cancer

Enrolment for pivotal Phase II/III trial of C-Cure completed ahead of schedule

Seattle Genetics announces collaboration to globally develop and commercialize brentuximab vedotin

ProChon Biotech announces expansion of BioCart Cartilage Regeneration System study

Modifications to Phase II study AD201 and open label extension study AD251 for ELND005 notified

New highly sensitive CFSE T cell proliferation assays launched by ProImmune

Mylan to be added to NASDAQ-100 Index

Dyadic International enters into collaboration agreement with The Scripps Research Institute

Teva Pharmaceutical Industries receives approval for newly revised prescribing information for AZILECT

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Vivakor launches new website to promote its remarkable VivaThermic Vial

Biotechnology eBook

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News